Piramal Pharma Solutions, a global contract development and manufacturing organization (CDMO), has collaborated with George Medicines to develop WIDAPLIK™, the first FDA-cleared triple combination therapy for hypertension that can be used as initial treatment in adults requiring multiple medications to reach blood pressure targets.
Science Significance
WIDAPLIK combines telmisartan, amlodipine, and indapamide in a single tablet, offering a multi-mechanism approach to lower blood pressure. By incorporating two lower-dose options than existing combinations, it is designed to optimize efficacy while maintaining a well-established safety profile, potentially improving adherence and patient outcomes in hypertension management.
Regulatory Significance
The U.S. Food and Drug Administration authorized WIDAPLIK on June 6, 2025, making it the first triple-combination therapy approved for initial hypertension treatment. The approval underscores the growing regulatory support for innovative multi-drug therapies that address unmet needs in cardiometabolic diseases.
Business Significance
Advertisement
The collaboration leverages Piramal Pharma Solutions’ global development and manufacturing expertise, spanning formulation, validation, and commercial production, to accelerate the availability of WIDAPLIK. This partnership enhances George Medicines’ market entry in the U.S. and global hypertension therapy segment, where more than one billion adults are affected worldwide.
Patients’ Significance
For patients requiring multiple antihypertensive agents, WIDAPLIK offers a convenient single-tablet solution with proven efficacy. Its availability as an initial therapy supports earlier blood pressure control, potentially reducing the risk of complications such as stroke, heart attack, and kidney disease.
Policy Significance
WIDAPLIK’s approval reflects the FDA’s emphasis on combination therapies to improve patient outcomes and adherence, aligning with broader public health policies aimed at reducing the global burden of hypertension.
Transaction Highlights
The development of WIDAPLIK began in December 2018 at Piramal Pharma Solutions’ Ahmedabad facility and progressed to commercial manufacturing at Pithampur, India, in 2020. The drug is available in three dosage strengths (10/1.25/0.625 mg, 20/2.5/1.25 mg, 40/5/2.5 mg) to accommodate individualized therapy needs. Piramal Pharma Solutions’ end-to-end CDMO capabilities, including formulation, scale-up, validation, and commercial supply, were integral to achieving FDA clearance and ensuring global patient access.
Source: Piramal Pharma Solutions Press Release
